Panel Discussion: From Signal to Strategy: How Liquid Biopsy is Rewriting Drug Development Decisions

• Turning ctDNA and MRD signals into faster, higher confidence go/no-go decisions across modalities
• Cutting years and cost from development by replacing slow endpoints with early molecular insight
• Making liquid biopsy work in the real world: global logistics, scalability, and ROI for sponsors

Speakers:

Kristiyana Kaneva

Senior Medical Director, Clinical Development, Oncology Early Development

Abbvie

Minakshi Guha

Associate Director, Precision and Translational Medicine

Takeda

Erica Schleifman

Senior Director, Cancer Biomarker Development

AstraZeneca

Rajiv Raja

Executive Director, Oncology Translational Medicine

GSK

Matthew Pink

Vice President, Business Development

Biodesix